Clinical Trial Detail

NCT ID NCT03313804
Title Priming Immunotherapy in Advanced Disease With Radiation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors John L. Villano, MD, PhD
Indications

lung non-small cell carcinoma

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Atezolizumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.